Biotech stocks attracted investors’ attention last year due to their role in developing vaccines and therapies to save the world from the COVID-19 pandemic. However, several industry participants have delivered disappointing stock market performance this year due to uncertain macroeconomic conditions.
Earlier this year, biologics company ReForm Biologics, Inc. renamed itself Comera Life Sciences Holdings, Inc. (CMRA).
